Spanish study checks Real-World use of MS drug ofatumumab

NCT ID NCT06251986

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study in Spain looked at 310 people with relapsing multiple sclerosis who were taking ofatumumab (Kesimpta®). Researchers wanted to see how well the drug reduced relapses and how safe it was in everyday medical practice. The study collected information from medical records and patient visits to understand the drug's real-world effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ofatumumab (Kesimpta®)
What this could lead to: If results are positive, this could confirm that ofatumumab is an effective and safe option for managing relapsing multiple sclerosis in real-world settings.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It also only looked at patients in Spain, so findings may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING FORMS OF MULTIPLE SCLEROSIS

Contacts and locations

Locations

Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

Palma, Balearic Islands, 07120, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Santander, Cantabria, 39008, Spain
Novartis Investigative Site

Albacete, Castille-La Mancha, 02006, Spain
Novartis Investigative Site

Salt, Girona, 17190, Spain
Novartis Investigative Site

Logroño, La Rioja, 26006, Spain
Novartis Investigative Site

Fuenlabrada, Madrid, 28942, Spain
Novartis Investigative Site

Majadahonda, Madrid, 28222, Spain
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Vigo, Pontevedra, 36212, Spain
Novartis Investigative Site

Santa Cruz, Santa Cruz de Tenerife, 38009, Spain
Novartis Investigative Site

Barakaldo, Vizcaya, 48903, Spain
Novartis Investigative Site

Alicante, 03010, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Burgos, 09006, Spain
Novartis Investigative Site

Cáceres, 10004, Spain
Novartis Investigative Site

Córdoba, 14004, Spain
Novartis Investigative Site

Granada, 18016, Spain
Novartis Investigative Site

León, 24080, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Madrid, 28040, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Madrid, 28046, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Seville, 41009, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Valencia, 46026, Spain
Novartis Investigative Site

Zaragoza, 50009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.